FGFR1 and sarcoma: With regard to FGFR inhibitors specifically used in sarcomas, there is a recent case report of a patient with TIO associated with metastatic PMT in which treatment with infigratinib, a FGFR1-3 TKI, dramatically decreased bone lesions [92].